{"url_path":"/sec/avtx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000033-index.html","accession_number":"0001534120-26-000033","cik":"0001534120","ticker":"AVTX","issuer_name":"Avalo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534120/0001534120-26-000033-index.html","primary_entity_key":"0001534120","primary_entity_name":"Avalo Therapeutics, Inc."},"word_count":61,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nInsider Trading Arrangements\n\nDuring the three months ended March 31, 2026, none of our directors or officers (as defined in rule 16a-1 (f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408 of Regulation S-K).\n\n35\n\n[Table of Contents](#ia91c2e9fd7f4434fb24288b227069962_7)"}